finally a new comprehensive study on NGAL levels in Neonatals. The measurements and the study was conducted by Docteur Roszyk and Docteur Sapin at:  Service de biochimie et biologie moléculaire, hôpital Estaing, CHU de Clermont-Ferrand, France – so as always there is reasons to cheer :
Vive la France..
The interesting aspect of the study (as our senior scientific editor/contributor Doc points out) that this study gives clear indication of “normal” values of NGAL – and helps define the range of “non-AKI-NGAL-Levels”
The study shows that the non-aki-level stretches up too 146 ng/ml – and that neonatals that can be considered “normal”  have up to 117 ng/ml  (99% of population)
The quality of NGAl as a marker is underlined by the fact that 75% of all healthy children have measurements of under 12 mg/ml… In the words of Doc “It’s a damn fine marker for children…”
The test have been carried out on an Abbott Architect analyzer, but there is no disclosure of which Test have been used (but its probably Abbotts own)
Previously we have seen studies that indicate that 140-145 ng/ml is within the upper quartil of Non-AKI-patients

About Stengaard

BioPorto investor from way back when... I've invested in BioPorto ever since they made their debut on the danish stock exchange, it been a looooong journey with many obstacles. But well worth it all if Bioporto maintains their patent after the proceedings in 2014, and enters into agreements with Global Distributors in 2012 and 2013 If not, then it'll take another xx.years 🙂

Tagged with:

Leave a Reply

Your email address will not be published. Required fields are marked *

Set your Twitter account name in your settings to use the TwitterBar Section.